We strive to establish ourselves as a prime provider of high quality antigens for vaccine and monoclonal antibody development. Our future goals are to achieve a full proof-of-concept of ProVaDis technology and identify the antigens for development of our first product, a therapeutic vaccine against acne vulgaris.
We are looking to develop successful collaborations with industry and additional academic partners who will complement our activities and help to expedite bringing our products to market. We will be also looking for the first private equity investments by the end of 2014.
We are in the process of active team-building, recruitment and fund-raising. Contact us for more information, if you would like to join our highly dynamic and innovative team.